Event-free survival extended with long-term finerenone in heart failure
By
HealthDay News
Sep 30, 2024
For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo.
Incidence of cardiovascular disease higher for seniors with cancer
By
HealthDay News
Sep 23, 2024
The greatest incidence was seen for metastatic, hematological and lung cancer; an increased risk for CVD was seen with chemotherapy.
Personality tied to cardiovascular disease risk with type 2 diabetes
By
HealthDay News
Sep 17, 2024
A lower diligence level was linked to the risk for new cardiovascular disease, but a healthy lifestyle still was beneficial.
Few with type 2 diabetes receive guideline-recommended CKD screening
Jul 01, 2024
24.9 percent received creatinine and UACR screening; Hispanic ethnicity associated with lack of screening
Triglyceride-glucose index independently linked to all-cause mortality
Jun 21, 2024
Association with in-hospital and one-year mortality seen for patients with heart failure and chronic kidney disease
AI screens patients for clinical trials with greater accuracy than staff
Jun 20, 2024
In addition to enhanced performance, automated screening cuts costs.
Nonphysician-implemented multifaceted intervention beneficial in HTN
Jun 20, 2024
Significant reductions were seen in total cardiovascular disease and all-cause mortality for those aged 60 years and older; significant reductions also were seen for those younger than 60 years.
Semaglutide reduces need for diuretics in heart failure
May 16, 2024
Medication also has a beneficial effect on the change in body weight across diuretic use categories.
ACC: Empagliflozin cuts heart failure hospitalization risk after AMI
Apr 08, 2024
Lower risks for first heart failure hospitalization and total heart failure hospitalization were seen with empagliflozin.